Janux Therapeutics, Inc. reported an insider ownership change involving David Alan Campbell on July 8, 2026, in a Form 4 filed July 10, 2026. The filing relates to Janux common stock and discloses a transaction covering 7,000 shares at $4.21 per share. The notation attached to the reported security states that it is “immediately exercisable,” indicating the reported item appears to be an option or other derivative right to acquire Janux common stock rather than a simple open-market stock purchase. The $4.21 figure is therefore best understood as the exercise price associated with the right to acquire the 7,000 underlying shares, based on the language provided. The filing text does not provide a transaction code, a post-transaction beneficial ownership total, or a detailed vesting schedule beyond the statement that the security is immediately exercisable. It also does not specify whether the award was granted under an equity incentive plan or whether it was connected to a board, employment, or consulting role. The Form 4 was signed on Campbell’s behalf by James Pennington, attorney-in-fact, on July 10, 2026. As a result, the key reported action is that Campbell obtained or reported an immediately exercisable right tied to 7,000 shares of Janux Therapeutics common stock at $4.21 per share as of July 8, 2026.